Log in
Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
2
clinical trials
|
View Analysis
Sort by:
Newest First
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Phase 3
Recruiting
Conditions
HR+/HER2- Breast Cancer
Advanced Breast Cancer
Interventions
Drug: Apatinib
Drug: CDK4/6 Inhibitor
Drug: Aromatase inhibitor and Fulvestrant
Subscribe
First Posted Date
2024-06-07
Last Posted Date
2024-06-07
Lead Sponsor
Fudan University
Target Recruit Count
184
Registration Number
NCT06447623
Locations
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Subscribe
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Phase 2
Recruiting
Conditions
Breast Cancer
Advanced Breast Cancer
Interventions
Drug: Everolimus 10 mg
Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Drug: CDK4/6 Inhibitor SHR6390
Subscribe
First Posted Date
2023-07-18
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
265
Registration Number
NCT05949541
Locations
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy